Here is the design of a clinical trial:

Official Title: Medico-economic Evaluation of the ONCORAL Program of Multidisciplinary ONCOlogic Interventions Between Town and Hospital (Doctor-pharmacist-nurse) for Ambulatory Patients Under oRAL Anticancer Drugs Versus Usual Care

Included conditions:
- Cancer

Study Armgroups:
- {'label': 'Interventional Arm', 'type': 'EXPERIMENTAL', 'description': 'Application of the ONCORAL program of multidisciplinary ONCOlogic interventions between town and hospital (doctor-pharmacist-nurse) for ambulatory patients under oRAL anticancer drugs', 'interventionNames': ['Behavioral: ONCORAL therapeutic education']}
- {'label': 'Standard of care', 'type': 'SHAM_COMPARATOR', 'description': 'Patients in the control group will receive regular follow-up from their oncologist, but no more that the standard care.', 'interventionNames': ['Behavioral: Standard of care']}

Interventions:
- {'type': 'BEHAVIORAL', 'name': 'ONCORAL therapeutic education', 'description': 'Multidisciplinary program that includes informative cessions with a hospital pharmacist about the anticancer drug: information is given to the patients on adverse events and their managements, optimizing drug dosage plans. Moreover, information is shared with town partners: doctor, pharmacists, and nurses.', 'armGroupLabels': ['Interventional Arm']}
- {'type': 'BEHAVIORAL', 'name': 'Standard of care', 'description': 'In the group of standard of care, patients will have interviews with a clinical research associate only dedicated to the record of data for outcomes assessments.', 'armGroupLabels': ['Standard of care']}

Primary Outcomes:
- {'measure': 'Evaluate efficiency of ONCORAL program for ambulatory patients under oral anticancer drugs versus usual care', 'description': 'Efficiency is calculated on the double dimension cost and year of life corrected by quality of life (QALY).', 'timeFrame': 'Month 12'}

Please estimate the sample size based on the assumption: 
The study is designed with an 80% power and a 0.05 two-sided significance level. An unbalanced 2:1 ratio in favour of the ONCORAL programme is used, and early withdrawal is accounted for.
Sample size calculation
          The sample size was based on RDI, as it is associated with the effectiveness of OAA. According to the information available in the literature at the time of the study design, its value was 0.70 in usual care.28 We assume that the ONCORAL programme will achieve the RDI of 0.85. For an unbalanced 2:1 ratio in favour of the ONCORAL programme, a sample of 130 patients in the ONCORAL group and 65 in the usual care group will achieve a power of 80% at a 0.05 two-sided significance to detect a difference of 0.15 with a SD of 0.35. To take into account early withdrawal from the study, a total of 215 patients will be included in the study (143 in the ONCORAL group and 72 in the usual care group).
          The number of patients treated with OAA in the study centre is approximately 350 per year, which will allow the recruitment of the expected number of subjects.